The absence of a pharmacokinetic interaction between aspirin and the angiotensin-converting enzyme inhibitor benazepril in healthy volunteers.

Author(s): Sioufi A, Pommier F, Gauducheau N, Godbillon J, Choi L, John V

Affiliation(s): Laboratoires Ciba-Geigy, Biopharmaceutical Research Centre, Rueil-Malmaison, France.

Publication date & source: 1994-08, Biopharm Drug Dispos., 15(6):451-61.

Publication type: Clinical Trial; Randomized Controlled Trial

Potential effects of the coadministration of single doses of aspirin (325 mg) and of benazepril hydrochloride (20 mg) on the pharmacokinetics and the metabolism of these two drugs were evaluated in 12 healthy subjects. Plasma concentration profiles of benazepril, its active metabolite benazeprilat, and total salicylic acid were determined together with urinary excretion of benazeprilat, salicylic acid, salicyluric acid, and salicylate glucuronides. Almost superimposable plasma profiles of benazepril, benazeprilat, and total salicylic acid were achieved with the drugs given alone and concomitantly. The coadministration of benazepril hydrochloride and aspirin did not modify the pharmacokinetics or the metabolism of the two drugs.